Longeveron granted Japan patent for potency assay methods for MSCs

Longeveron (LGVN) announced that the Japan Patent Office, JPO, has granted a patent covering potency assay methods for assessing human mesenchymal stem cells, MSCs, derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells, IPSCs. Japan Patent No. 2022-563984, entitled “Potency Assay,” provides Longeveron with patent rights in Japan through April 20, 2041, assuming all annuity fees are paid. Potency assays are a crucial element for approved cell-based therapy products. “We are extremely encouraged by our growing portfolio of international patents protecting the novelty of our cell-based therapeutic products,” said Dr. Joshua Hare, Executive Chairman and Chief Science Officer of Longeveron. “This issuance brings Longeveron’s global intellectual property portfolio to 33 issued patents.”